- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Marlborough Today
By the People, for the People
Boston Scientific Shares Hit New 1-Year Low Amid Lawsuits and Regulatory Concerns
Multiple law firms file class actions alleging misleading statements about product safety and the company's electrophysiology business
Published on Mar. 10, 2026
Got story updates? Submit your updates here. ›
Shares of Boston Scientific Corporation (NYSE:BSX) reached a new 52-week low on Tuesday, trading as low as $69.52 amid growing legal and regulatory risks. Several law firms have filed or announced class action lawsuits on behalf of BSX investors, citing a Class I recall of the AXIOS Stent & Delivery System, a federal probe into the company's disclosures and product safety, and allegations of misleading statements about the U.S. electrophysiology business.
Why it matters
The legal and regulatory issues facing Boston Scientific could lead to settlements, fines, and reputational damage, potentially weighing on the company's earnings and cash flow. Investors are closely watching how the company navigates these challenges and whether it can maintain confidence in its capital returns and growth plans.
The details
The lawsuits and investigations cover the July 23, 2025 to February 3, 2026 period, with lead-plaintiff deadlines set for May 4, 2026 in several notices. The legal issues come as Boston Scientific negotiated a new $3.0 billion revolving credit facility, expanded its share-repurchase authorization to $5.0 billion, and added two senior healthcare/finance leaders to its board - moves that could bolster liquidity and signal confidence, but may also be an attempt to address the underlying concerns.
- Shares of Boston Scientific reached a new 52-week low on Tuesday, March 10, 2026.
- The lawsuits and investigations cover the July 23, 2025 to February 3, 2026 period.
- Lead-plaintiff deadlines have been set for May 4, 2026 in several of the class action notices.
The players
Boston Scientific Corporation
A global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures.
Rosen Law Firm
A law firm that has filed a class action lawsuit on behalf of BSX investors.
Levi & Korsinsky
A law firm that has filed or announced a class action investigation on behalf of BSX investors.
Robbins LLP
A law firm that has filed a class action lawsuit on behalf of BSX investors.
Bronstein, Gewirtz & Grossman, LLC
A law firm that has filed a class action lawsuit on behalf of BSX investors.
What they’re saying
“We must hold Boston Scientific accountable for its alleged misleading statements and failure to disclose material information to investors.”
— Phillip Kim, Partner, Levi & Korsinsky (Levi & Korsinsky Press Release)
What’s next
The judge in the case will decide on May 4, 2026 whether to allow the class action lawsuits to proceed.
The takeaway
The legal and regulatory challenges facing Boston Scientific highlight the risks that medical device companies can face from product safety issues and alleged disclosure failures. Investors will be closely watching how the company navigates these headwinds and whether it can maintain confidence in its long-term growth strategy.
